[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Central Hospital, Nancy, France\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":589},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,125,0,25,[9,38,69,90,113,133,155,175,194,220,242,261,280,301,323,342,375,396,421,444,470,493,519,542,570],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100054015","eating-disorders-in-patients-with-phenylketonuria-100054015",false,"NCT07698743","Eating Disorders in Patients With Phenylketonuria","TCA-PKU","Inclusion Criteria:\n\n* Subjects followed for PKU at Nancy University Hospital\n* Subjects willing to participate\n\nExclusion Criteria:\n\n* Subjects not villing to participate","ALL",{"count":19,"type":20},70,"ESTIMATED","OBSERVATIONAL","The prevalence of eating disorders and BMI are significantly higher in PKU patients than in the general population. The protein-restricted diet associated with high carbohydrate intake and the severity of the genetic defect and disease can lead to weight gain in these patients; However, the link between restrictive diets, EDs, and obesity has not been demonstrated in patients with PKU. These issues remain poorly explored, meaning that patients may not be detected and treated.",[24],"Phenylketonuria","RECRUITING","2026-07-07",{"date":28,"type":29},"2026-07-13","ACTUAL",{"date":31,"type":29},"2025-12-04",{"date":33,"type":20},"2028-04-02",{"name":35,"class":36},"Central Hospital, Nancy, France","OTHER",1,{"id":39,"slug":40,"hasResults":12,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":12,"sex":17,"minAge":46,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":37},"100645198","time-controlled-adaptive-ventilation-tcav-compared-with-conventional-ventilation-in-patients-with-moderate-to-severe-acute-respiratory-distress-syndrome-ards-secondary-to-community-acquired-pneumonia-100645198","NCT07679802","Time-controlled Adaptive Ventilation (TCAV) Compared With Conventional Ventilation in Patients With Moderate-to-severe Acute Respiratory Distress Syndrome (ARDS) Secondary to Community-acquired Pneumonia","Efficacy and Safety of Time-controlled Adaptive Ventilation (TCAV) Compared With Conventional Ventilation in Patients Requiring Invasive Ventilation for Moderate-to-severe Acute Respiratory Distress Syndrome (ARDS) Secondary to Community-acquired Pneumonia","EARLY-TCAV","Inclusion Criteria:\n\n* Intensive care unit hospitalisation for ARDS with a PaO₂\u002FFiO₂ ratio ≤ 200 mmHg and PEEP ≥ 5 cmH₂O under invasive ventilation\n* Criteria for community-acquired pneumonia, 2 of the following: cough, purulent sputum, chest pain, dyspnea\n* Onset of symptoms ≤ 7 days\n* Invasive ventilation initiated ≤ 24 hours\n* Affiliation to a social security program\n* Patient for whom written consent has been obtained from a trusted person or a family member, or inclusion in a situation of immediate life-threatening emergency\n\nExclusion Criteria:\n\n* Focal ARDS defined as unilateral involvement (1 out of 4 quadrants or 2 on the same side) on imaging (chest X-ray or CT scan)\n* Right heart failure not related to acute pulmonary heart disease secondary to ARDS (pulmonary embolism, myocarditis, ischemic cause)\n* Pneumothorax, drained or undrained, with a persistent pleural air leak\n* COPD with significant obstructive impairment defined by the presence of chronic respiratory disease and oxygen therapy or non-invasive ventilation at home\n* Circulatory support via VV-ECMO or VA-ECMO\n* Presence of a patent foramen ovale\n* Active limitation of therapies\n* Increased intracranial pressure\n* Sickle cell disease\n* Burns \\> 30%\n* Expected invasive mechanical ventilation for less than 48 hours\n* A person covered by Articles L. 1121-5, L. 1121-7, and L. 1121-8 of the French Public Health Code\n* Pregnant or breastfeeding women\n* A not emancipated minor\n* Adults subject to legal protective measures (guardianship, conservatorship, judicial protection) or inability to give consent\n* Persons deprived of liberty by a judicial or administrative decision, persons receiving psychiatric care pursuant to Articles L. 3212-1 and L. 3213-1","18 Years",{"count":48,"type":20},56,"INTERVENTIONAL",[51],"NA","ARDS is a pathology with mortality rates reaching 40%. Invasive ventilation, the cornerstone of ARDS management, leads to \"ventilation-induced lung injury\" (VILI). An approach based on pressure-controlled ventilation with unassisted spontaneous respirations (PC-SV or APRV) can limit the occurrence of VILI. Time-controlled adaptive ventilation (TCAV) is based on high mean inspiratory airway pressure, while limiting expiratory time at low pressure. TCAV has shown positive effects in experimental and observational studies. However, its efficacy and safety in patients with moderate-to-severe ARDS remains to be evaluated.\n\nEvaluation of the efficacy of early application of TCAV compared to standard ventilation on the severity of alveolar damage leading to injury-related pulmonary edema in patients with moderate to severe ARDS After obtaining patient's consent, eligible patients will be included in this open-label, randomized controlled pilot study with stratification by minimization based on initial severity. The experimental group will be the TCAV group, where ventilator settings will be standardized. The ventilator in the standard care group will be set to volumetric mode with positive end-expiratory pressure according to the EXPRESS protocol.\n\nThe measurement of extravascular lung water will be compared on day 2 between the TCAV settings group and the standard care settings group using the PICCO system.\n\nThe TCAV setting is simple and inexpensive. In ARDS patients, the increase in injury-related pulmonary edema is a relevant marker of mortality, and its reduction could improve patients' outcomes. Our study aims to evaluate the efficacy and safety of these settings to justify a future large-scale, multicenter randomized trial.",[54],"ARDS (Acute Respiratory Distress Syndrome)",[56,57,58,59],"ARDS","APRV","TCAV","Invasive ventilation","NOT_YET_RECRUITING","2026-06-30",{"date":63,"type":29},"2026-07-01",{"date":65,"type":20},"2026-10-01",{"date":67,"type":20},"2028-11-30",{"name":35,"class":36},{"id":70,"slug":71,"hasResults":12,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":12,"sex":17,"minAge":46,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":4},"100644938","performance-of-amino-acid-pet-in-brain-metastases-100644938","NCT07676448","Performance of Amino Acid PET in Brain Metastases","Static and Dynamic Performance of Amino Acid PET for Differentiating Radiation Necrosis From Tumor Progression in Irradiated Brain Metastases (DYNAMET)","DYNAMET","Inclusion Criteria:\n\n* Patients who received a PET amino acid for differentiating radiation necrosis from progression of irradiated brain metastases,\n\nExclusion Criteria:\n\n* Patients who refused the using of their data","90 Years",{"count":79,"type":20},80,"Differentiating radiation necrosis from tumor progression in patients with brain metastases has a major therapeutic and prognostic implications",[82],"PET-CT","2026-06-24",{"date":61,"type":29},{"date":86,"type":20},"2026-08-05",{"date":88,"type":20},"2026-11-03",{"name":35,"class":36},{"id":91,"slug":92,"hasResults":12,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":12,"sex":17,"minAge":46,"maxAge":98,"enrollmentInfo":99,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":101,"conditions":102,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},"100616707","deep-learning-on-amyloid-positons-emission-tomography-100616707","NCT07309107","Deep Learning on Amyloid Positons Emission Tomography","Impact of Deep Learning-Based Noise Reduction Algorithm on Visual Analysis and Centiloid Quantification in Reduced-Dose and, or Time Acquisition Amyloid PET Imaging","DEEPAMY","Inclusion Criteria:\n\n* Patients with objective cognitive impairment,\n* Referred to our department for a cerebral \\[¹⁸F\\]flutemetamol positron emission tomography scan between January 1, 2023 and July 1, 2025,\n\nExclusion Criteria:\n\n* Patient have objected to the use of their data.","99 Years",{"count":100,"type":20},40,"Reducing injected dose and\u002For acquisition time in amyloid PET imaging would improve comfort, radiation safety and cost-effectiveness in diagnosis and follow-up of patients. This study evaluates the impact of a deep learning-based noise reduction algorithm on visual analysis and Centiloid quantification when simulating reduced injected doses of \\[18F\\]flutemetamol.",[103],"Alzheimer Disease","2026-06-23",{"date":106,"type":29},"2026-06-25",{"date":108,"type":29},"2026-05-06",{"date":110,"type":20},"2027-01-30",{"name":35,"class":36},3,{"id":114,"slug":115,"hasResults":12,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":12,"sex":17,"minAge":46,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":49,"phases":123,"briefSummary":124,"conditions":125,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":127,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":37},"100552044","heart-analysis-in-gated-pet-in-patients-having-a-gallium-68-dotatoc-petct-exam-for-oncology-indication-100552044","NCT06467968","Heart Analysis in GATED-PET in Patients Having a Gallium-68-DOTATOC PET\u002FCT Exam for Oncology Indication","GATED-PET Heart Analysis in Patients Having a Gallium-68--DOTATOC PET\u002FCT Exam for Oncology Indication","GATEDOTA","Inclusion Criteria:\n\nPersons who have received complete information on the organization of the research and who have signed the informed consent and:\n\n* Age ≥ 18 years old.\n* Having read and understood the information document.\n* Affiliated to a social security scheme.\n\nPerson for whom a 68Ga-DOTATOC PET\u002FCT exam is requested as part of the diagnostic or pre-therapeutic assessment of a neuroendocrine tumour.\n\nExclusion Criteria:\n\nPerson with\n\n* Hypersensitivity during previous use of 68Ga-DOTATOC\n* Impossibility of performing a PET-CT (patient agitated, confused, etc.).\n* History of heart disease,\n* Severe arrhythmia that does not allow the PET synchronized with the ECG\n* Severe renal insufficiency (GFR \\\u003C30 ml\u002Fmin\u002F1.73 m2)\n* Treated with a somatostatin analogue.\n* Cushing's syndrome\n* Pregnant woman, likely to be or breastfeeding\n* Adult subject to a legal protection measure (guardianship, curators, legal safeguard)\n* Person of legal age unable to express their consent\n* Person deprived of liberty by a judicial or administrative decision\n* Person, subject to psychiatric care under articles L. 3212-1 and L. 3213-1",{"count":122,"type":20},99,[51],"Gallium-68-DOTATOC binds primarily with high affinity to somatostatin subtype 2 (SSTR2) receptors and these somatostatin receptors are also overexpressed on inflammation cells when activated.\n\nThe hypothesis is that the GATED mode on a Gallium-68-DOTATOC cardiac recording would be able to highlight abnormalities that could be correlated with the age of the patients and their cardiovascular risk factors.",[126],"Cardiac Inflammation",{"date":106,"type":29},{"date":129,"type":29},"2023-02-02",{"date":131,"type":20},"2027-05-26",{"name":35,"class":36},{"id":134,"slug":135,"hasResults":12,"nctId":136,"briefTitle":137,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":12,"sex":17,"minAge":46,"maxAge":140,"enrollmentInfo":141,"targetDuration":4,"studyType":49,"phases":143,"briefSummary":145,"conditions":146,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":148,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":154},"100525811","phase-2-combination-of-everolimus-and-177lu-dotatate-in-the-treatment-of-grades-2-and-3-refractory-meningioma-a-phase-iib-clinical-trial-100525811","NCT06126588","Combination of Everolimus and 177Lu-DOTATATE in the Treatment of Grades 2 and 3 Refractory Meningioma: a Phase IIb Clinical Trial","ELUMEN","Inclusion Criteria:\n\n* Adult patient \\\u003C 80 years old, who received a complete comprehensive briefing about the trial and signed the informed consent\n* Eligible patient for compassional access program (National Multidisciplinary Neuro-Oncology board to Lutathera ® traitement\n* WHO performance status ≤ 3\n* Patient with grade 2 and 3 meningioma, substantiated by histology, not amenable to surgery or radiotherapy, with clinical or radiological progression\n* Clinical deterioration or at least 10% of tumor growth rate, defined as the product of the two largest diameters of the target lesion within 6 months\n* Expressing somatostatin receptors as determined by 68Ga-DOTATOC PET (lesion uptake ≥ liver uptake and\u002For 1.7 fold SUVpeak of the controlateral meninges).\n* Patient that underwent a brain MRI and 68Ga-DOTATOC PET within the last 2 months.\n* Effective contraception required for women of childbearing age.\n* Patient with social security cover.\n\nExclusion Criteria:\n\n* Hypersensitivity to everolimus.\n* Contraindication to 177Lu-DOTATATE: renal failure GFR\\\u003C40 mL\u002Fmin\u002F1.73m2 (calculated by the CKD-Epi Formula), hepatic failure total bilirubin \\>3N, heart failure NYHA III or IV.\n\nPatients should not take the following treatments:\n\n* Other rapamycin derivatives (sirolimus, temsirolimus, deforolimus).\n* Other immunosuppressants\n* Co-administration with potent inhibitors and inducers of CYP3A4 and\u002For the multidrug efflux pump P-glycoprotein (PgP) : Ketoconazole , itraconazole, posaconazole, voriconazole, telithromycin, clarithromycin, Nefazodone, Ritonavir, atazanavir, saquinavir, darunavir, indinavir, nelfinavir.\n* If everolimus is taken with orally administered CYP3A4 substrates with a narrow therapeutic index (e.g. pimozide, terfenadine, astemizole, cisapride, quinidine or ergot alkaloid derivatives), the patient should be monitored for undesirable effects described in the product information of the orally administered CYP3A4 substrate.\n* Contraindication to MRI or 68Ga-DOTATOC PET\u002FCT.\n* Person referred to and L. 3212-1 and L. 3213-1 (psychiatric care).\n* Women of childbearing age without effective contraception\n* Patient unable to attend follow-ups over a 12-month period.\n* Patients who participate in an interventional clinical research trial for the duration of the ELUMEN study.\n* Individuals referred to in Articles 10, 31, 32, 33 and 34 of Regulation (EU) No 536\u002F2014.\n* Pregnant woman, birthing or breastfeeding mother\n* Minor (not emancipated)\n* Adult subject to a legal protection measure (such as guardianship, conservatorship)\n* Adult who is unable to give consent","80 Years",{"count":142,"type":20},28,[144],"PHASE2","Meningioma, the most common intracranial primary tumor of the central nervous system predominantly affects people in their fifties. Meningiomas are generally subdivided into two entities: a priori non-aggressive meningiomas (grade 1), and meningiomas at high risk of aggressive behavior (grade 2\u002Fatypical and 3\u002Fanaplastic). The current conventional treatments for meningioma are surgery and radiotherapy. When these treatments are no longer feasible, meningiomas are considered refractory irrespectively of grade, and in these rare entities, the therapeutic arsenal is reduced to the few treatments that have shown limited efficacy. Refractory, and particularly grades 2 and 3 meningiomas, have very poor prognoses with a progression-free survival at 6 months (PFS-6) of 26%. The European Response Assessment in Neuro-Oncology group (RANO) recommends that in any new, grades 2 and 3 meningioma, therapy that achieves a PFS-6 \\>30% in phase II trials be considered promising.\n\nIn Nuclear Medicine, Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE, currently used on a compassionate basis in refractory meningioma, deploys an octreotide-like effect, and appears very promising, with preliminary PFS-6 of 94% and an overall survival at 12 months (OS-12) of 88% in grade 1 meningioma. However, its PFS-6 is reduced to 28% with an OS-12 of 65% in WHO grades 2 and 3 meningioma. Recently the non-radiolabeled octreotide and everolimus combination however achieved a PFS-6 of 55% and an OS-12 of 75% in a population of 90% WHO grades 2 and 3 meningioma.",[147],"Meningioma",{"date":106,"type":29},{"date":150,"type":29},"2024-11-29",{"date":152,"type":20},"2028-05-01",{"name":35,"class":36},2,{"id":156,"slug":157,"hasResults":12,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":12,"sex":17,"minAge":46,"maxAge":77,"enrollmentInfo":163,"targetDuration":4,"studyType":49,"phases":165,"briefSummary":166,"conditions":167,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":169,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":37},"100511096","contribution-of-multiparametric-analysis-in-bone-scintigraphy-for-the-characterisation-of-solitary-bone-lesions-100511096","NCT05934994","Contribution of MUltiparametric Analysis in Bone Scintigraphy for the Characterisation of Solitary Bone Lesions","Contribution of MUltiparametric Analysis in Bone Scintigraphy for the Characterisation of Solitary Bone Lesions Whose Malignant Origin Cannot be Excluded on Conventional Imaging","MUSIC","Inclusion Criteria:\n\n* Person, having received complete information on the organization of the research and having signed the informed consent and:\n\n  * Age ≥ 18 years old.\n  * Having read and understood the information document.\n  * Affiliated to a social security scheme.\n* Patient with an indeterminate solitary bone lesion on conventional imaging, for which an indication for biopsy +\u002F- excision is planned.\n\nExclusion Criteria:\n\n* Pregnant woman or woman of childbearing age and without contraceptive means or nursing mother.\n* Unstable medical condition and\u002For inability to remain still during recordings.\n* Known allergy to one of the components of the radiopharmaceutical technetium-99m-Technescan HDP (product required to perform the bone scan).\n* Person referred to in Articles L. 1121-5, L. 1121-7 and L1121-8 of the Public Health Code.\n* Persons deprived of their liberty by a judicial or administrative decision, persons subject to psychiatric care under articles L. 3212-1, L. 3213-1",{"count":164,"type":20},68,[51],"The hypothesis of the study is that non-invasive Single photon emission computed tomography (SPECT-CT) bone scintigraphy makes it possible to better characterize solitary bone lesions, in particular the exclusion of their malignancy in order to avoid unnecessary biopsy and possible complications for the patient.",[168],"Bone Lesion",{"date":106,"type":29},{"date":171,"type":29},"2023-09-11",{"date":173,"type":20},"2027-01-10",{"name":35,"class":36},{"id":176,"slug":177,"hasResults":12,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":181,"eligibilityCriteria":182,"healthyVolunteers":12,"sex":17,"minAge":46,"maxAge":4,"enrollmentInfo":183,"targetDuration":4,"studyType":49,"phases":184,"briefSummary":185,"conditions":186,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":188,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":37},"100453361","spectct-bone-scan-quantification-surgery-100453361","NCT05183542","SPECT\u002FCT Bone Scan Quantification Surgery","Predictive Performance of SPECT\u002FCT Bone Scan Quantification Before Lumbar Arthrodesis","PERQUAL","Inclusion Criteria:\n\n* Persons with back pain for at least 3 months (presumed to be due to degenerative disc disease or spondylolisthesis).\n* Persons who have received full information about the organisation of the research and have signed the informed consent and :\n\n  * Age ≥ 18 years, having read and understood the information document.\n  * Affiliated to a social security scheme.\n* Lumbar arthrodesis involving a maximum of 2 floors.\n* Standardized lumbar arthrodesis surgery performed by one of the three senior neurosurgeons of the neurosurgery department of the Nancy CHRU, using similar surgical techniques.\n\nExclusion Criteria:\n\n* Low back pain of neuropathic origin. The Neuropathic Pain Scale 4 questionnaire is used to diagnose neuropathic pain (score is ≥ 4\u002F10)\n* History of lumbar spine surgery\n* Presence of other pathologies responsible for lumbar pain (multistage discopathies, ankylosing spondylitis, spondylodiscitis, rheumatoid arthritis, vertebral compression, vertebral metastasis, narrow lumbar canal, scoliosis, spondylolisthesis by isthmic lysis)\n* Pregnant women or women of childbearing age without suitable contraception or nursing mothers.\n* Unstable medical condition and\u002For inability to remain immobile in supine position during recordings.\n* Known allergy to any component of the radiopharmaceutical (TECHNESCAN HDP).\n* Person referred to in Articles L. 1121-5, L. 1121-7 and L1121-8 of the Public Health Code.\n* Persons deprived of their liberty by a judicial or administrative decision, persons under psychiatric care by virtue of Articles L. 3212-1 and L. 3213-1.\n* Persons of full age who are unable to express their opposition.",{"count":19,"type":20},[51],"The hypothesis of our study is that SPECT\u002FCT bone scan fixation quantified by SUVMAX on a CZT solid state camera preoperatively would identify good responders to lumbar arthrodesis surgery.",[187],"Pseudoarthrosis of Bone",{"date":106,"type":29},{"date":190,"type":29},"2022-04-29",{"date":192,"type":20},"2027-11-29",{"name":35,"class":36},{"id":195,"slug":196,"hasResults":12,"nctId":197,"briefTitle":198,"officialTitle":198,"acronym":199,"eligibilityCriteria":200,"healthyVolunteers":201,"sex":17,"minAge":46,"maxAge":4,"enrollmentInfo":202,"targetDuration":4,"studyType":49,"phases":204,"briefSummary":205,"conditions":206,"keywords":210,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":154},"100531249","gastro-intestinal-biopotential-recorder-by-means-of-surface-electrodes-100531249","NCT06197334","Gastro-intestinal Biopotential Recorder by Means of Surface ELEctrodes","GRELE","Inclusion Criteria for all participants:\n\n* Person age \\> 18 years\n* Person has been fasting for at least 12 hours\n* Person who has received full information on the organization of the research and has not objected to the use of this data.\n* Person affiliated to or beneficiary of a social security plan\n* Person informed about study organization and having signed the informed consent\n\nInclusion Criteria for healthy volunteers :\n\n* Person has no history of chronic gastro-intestinal disease\n* Person has no acute of gastro-intestinal disease\n\nInclusion Criteria for Crohn's disease patients without fibrosis :\n\n* Person is already diagnosed with Crohn's disease\n* Person has underwent during the last 6 months :\n* An MRI showing no fibrosis\n* A blood test for C-reactive protein and fecal calprotectine\n* A questionnaire to asses the Harvey-Bradshaw Index\n\nInclusion Criteria for Crohn's disease patients with fibrosis :\n\n* Person is already diagnosed with Crohn's disease\n* Person has underwent during the last 6 months :\n* An MRI showing fibrosis\n* A blood test for C-reactive protein and fecal calprotectine\n* A questionnaire to asses the Harvey-Bradshaw Index\n\nInclusion Criteria for functional gastrointestinal disorders patients :\n\n* Person is already diagnosed with functional gastrointestinal disorders\n* Person has underwent an evaluation of the Rome IV criteria\n\nExclusion Criteria for all participants:\n\n* Person having a pacemaker\n* Person suffering from a sensory disorder making insensitive to pain on the skin\n* Person suffering from a mental or motor disorders creating uncontroled movements\n* Person being allergic to one or more component of the device\n* Person being allergic to : soy, dairy food, peanuts, wheat, nuts\n* Person having an history of gastro-intestinal surgery\n* Person suffering from injury or erythema on the abdominal skin\n* Person having a contagious potential (bacterial, fungal or viral)\n* Person being in menstruation period\n* Person suffering from urinary incontinence\n* Minor (not emancipated)\n* Person of legal age (subject to a legal protection measure)\n* Adult unable to give consent",true,{"count":203,"type":20},60,[51],"The goal of this clinical trial is to compare the gastro-intestinal biopotentials recorded with a homemade device using surface electrodes placed on the abdomen in healthy volunteers, Crohn's disease patients without fibrosis, Crohn's disease patients with fibrosis and in functional gastrointestinal disorders (FGID) patients.\n\nThe main question it aims to answer is:\n\n• Is there any differences in the gastro-intestinal biopotentials between the different populations under study?\n\nIt aims to answer two secondary questions:\n\n* Are the gastro-intestinal biopotentials comparable to the Harvey-Bradshaw Index, MRI and biological data for patients with Crohn's disease?\n* Are the gastro-intestinal biopotentials comparable to Rome IV criteria for functional gastrointestinal disorders patients?\n\nParticipants will undertake two recordings made with the device. The first one will last 1 hour and 30 minutes and will occurs while the participants are fasting. Then, the participants will eat a standardized meal. Finally, the second recording will take place after the meal ingestion and will last 1 hour and 30 minutes while the participants are in postprandial state.",[207,208,209],"Crohn Disease","Functional Gastrointestinal Disorders","Healthy",[211,212],"Medical device","Electrophysiology","2026-06-19",{"date":83,"type":29},{"date":216,"type":29},"2025-02-18",{"date":218,"type":20},"2027-09-01",{"name":35,"class":36},{"id":221,"slug":222,"hasResults":12,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":226,"eligibilityCriteria":227,"healthyVolunteers":201,"sex":17,"minAge":46,"maxAge":4,"enrollmentInfo":228,"targetDuration":4,"studyType":49,"phases":230,"briefSummary":231,"conditions":232,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":154},"100361232","identification-of-fecal-microbiota-biomarkers-of-spondyloarthritis-in-patients-suffering-from-crohns-disease-100361232","NCT03983473","Identification of Fecal Microbiota Biomarkers of Spondyloarthritis in Patients Suffering From Crohn's Disease.","Identification of Fecal Microbiota Biomarkers of Spondyloarthritis in Patients Suffering From Crohn's Disease. Identification de Biomarqueurs de SPondylArthrite Chez Les Patients Atteints de Maladie de CROhn présents Dans le MICrobiote fécal.","MICROSPA","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Patients will be recruited according to 3 groups:\n* Patients with Crohn's disease and axial spondyloarthritis according to the criteria below.\n* Patients with Crohn's disease (MC patients) with a diagnosis established according to clinical, biological criteria, radiological, endoscopic and \u002F or histological studies for 3 months. With diagnosis of exclusion of a spondyloarthritis on criteria ASAS and \u002F or New York modified.\n* Patients with axial spondyloarthritis (SpA patients) with a diagnosis based on modified ASAS and \u002F or New York criteria with exclusion diagnosis of Crohn's disease.\n* Patient with the ability to give free and express informed consent.\n\nExclusion Criteria:\n\n* History of colonic resection\n* Taking antibiotics or colon preparation for colonoscopy within 8 weeks before stool collection (Temporary contraindication = removal possible before colic or first bowel preparation after the start of colonic preparation).\n* Ostomy at the time of sampling\n* BMI\\> 30\n* extreme diet\n* unbalanced diabetes\n* Pregnant woman\n* Patient under guardianship, under curatorship or under the protection of justice Contacts\u002FLocations Central Contact",{"count":229,"type":20},240,[51],"The MICROSPA project aims to compare gut microbiota, serum cytokines, and PBMC of patients suffering from Crohn's disease (CD) associated or not to spondylarthritis (SpA). 3 groups of patients will be analyzed: patients suffering from CD alone, patients suffering from SpA alone, patients suffering from CD and SpA. One group of healthy controls will be analysed as a comparator. Fecal microbiota will be determined by bacteriome, virome and fungome NGS sequencing",[207,233],"Spondyloarthritis","2026-06-17",{"date":236,"type":29},"2026-06-18",{"date":238,"type":29},"2021-11-16",{"date":240,"type":20},"2027-12-16",{"name":35,"class":36},{"id":243,"slug":244,"hasResults":12,"nctId":245,"briefTitle":246,"officialTitle":246,"acronym":247,"eligibilityCriteria":248,"healthyVolunteers":201,"sex":17,"minAge":46,"maxAge":4,"enrollmentInfo":249,"targetDuration":4,"studyType":49,"phases":250,"briefSummary":251,"conditions":252,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":37},"100521512","characterization-of-normal-and-pathological-morphological-variations-of-the-temporomandibular-joint-by-real-time-magnetic-resonance-imaging-100521512","NCT06070558","ChAracterization of Normal and Pathological moRphological Variations of the TEMporomandibular Joint by Real-time magnetIc reSonance Imaging","ARTEMIS","Inclusion Criteria:\n\n* Adult: age ≥ 18 years old;\n* Person with the capacity to understand the instructions given;\n* Person affiliated to a social security scheme or beneficiary of such a scheme;\n* Person having received complete information on the organization of the Clinical Investigation and having signed informed consent.\n\nExclusion Criteria:\n\n* Person with large-scale metallic dental reconstructions;\n* Edentulism more than 5 teeth;\n* Claustrophobia;\n* Contraindication to performing an MRI examination\n* Persons referred to in Articles 64, 65 and 66 of European Regulation 2017\u002F745 on Medical Devices (RDM) and in L. 1121-5 to L1121-8 of the French Public Health Code",{"count":203,"type":20},[51],"The Real Time MRI Rapid Flash sequence is particularly interesting for the study of moving organs and joints.\n\nThis sequence will make it possible to characterize normal and pathological temporomandibular joint movements by MRI.",[209,253],"Temporomandibular Joint Disorders","2026-06-16",{"date":234,"type":29},{"date":257,"type":29},"2023-12-12",{"date":259,"type":20},"2026-12-12",{"name":35,"class":36},{"id":262,"slug":263,"hasResults":12,"nctId":264,"briefTitle":265,"officialTitle":265,"acronym":266,"eligibilityCriteria":267,"healthyVolunteers":201,"sex":17,"minAge":46,"maxAge":4,"enrollmentInfo":268,"targetDuration":4,"studyType":49,"phases":270,"briefSummary":271,"conditions":272,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":274,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":37},"100456045","evaluation-of-methodological-and-technical-developments-to-improve-the-quality-and-comfort-of-magnetic-resonance-imaging-exam-on-voluntary-subjects-100456045","NCT05218460","Evaluation of Methodological and Technical DEvelopmeNts to Improve the Quality and Comfort of Magnetic Resonance Imaging Exam on Voluntary Subjects","EDEN","Inclusion Criteria for all subjects :\n\n* to be over 18 year-old,\n* to be enrolled in a social security plan,\n* to have underwent a pre-inclusion medical examination,\n* to give a written consent.\n\nInclusion Criteria for volunteers with pathology :\n\n\\- person with a pathology characterized by a functional and \u002F or morphological alteration that may have an impact on the data collected (images, physiological signals, ...).\n\nExclusion Criteria for all subjects :\n\n* any contraindication to MR examination (active medical device, ferromagnetic foreign body, pregnancy, morbid obesity, claustrophobia, … ),\n* subject under a measure of legal protection,\n* Person who refuses to be informed by a doctor in th event of a fortuitus discovery of an abnormality on the MRI examination requiring additionnal examinations or specific treatment.",{"count":269,"type":20},720,[51],"The EDEN study will make it possible to evaluate one or more development phases (from design to validation through optimization) of a method or a technique on voluntary subjects, in normal or pathological condition.",[209,273],"Pathology",{"date":234,"type":29},{"date":276,"type":29},"2022-05-23",{"date":278,"type":20},"2027-05-23",{"name":35,"class":36},{"id":281,"slug":282,"hasResults":12,"nctId":283,"briefTitle":284,"officialTitle":284,"acronym":285,"eligibilityCriteria":286,"healthyVolunteers":12,"sex":287,"minAge":46,"maxAge":4,"enrollmentInfo":288,"targetDuration":4,"studyType":49,"phases":290,"briefSummary":291,"conditions":292,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":295,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":37},"100387730","mri-screening-of-placenta-adhesion-abnormalities-100387730","NCT04328532","MRI Screening of Placenta Adhesion Abnormalities","DIANE","Inclusion Criteria:\n\n* Pregnant participant between 30 and 38 weeks of gestation,\n* Age ≥18 years old,\n* Participant who completed the preliminary medical examination,\n* Participant who has received full information about the organization of the research and has signed her informed consent.\n* Participant planning to give birth at CHRU of Nancy\n* Participant presenting risk factors for PAA : low-lying or covering placenta or in front of the uterine scar.\n\nExclusion Criteria:\n\n* Multiple pregnancy,\n* Participant presenting at least one contraindication or restriction to performing an MRI as described in the protocol, in accordance with the current recommendations,\n* Participant unable to understand or follow study procedure,\n* Person referred to in Articles L. 1121-6 to L. 1121-8, L1122-2 and L. 1122-1-2 of the Public Health Code.","FEMALE",{"count":289,"type":20},71,[51],"Placenta Adhesion Abnormalities (PAA) are the consequence of an excessive invasion of the placenta within the myometrium. PAA are related to severe maternal pregnancy outcomes, especially in case of incidental discovery during delivery that increase the risk of intraoperative massive bleeding, hysterectomy and even maternal death. Ultrasound is the standard modality for diagnosing PAA, but Magnetic Resonance Imaging (MRI) has been increasingly performed in the case of inconclusive sonographic findings. However, standard morphological MRI sequences appear as insufficient to improve the sensitivity and specificity values for detecting PAA, while quantitative MRI may be more efficient.\n\nThe main objective of this study is to characterize the diagnostic performance of quantitative MRI parameters (mainly Apparent Diffusion Coefficient, T2 and T2\\*) reflecting placental perfusion and\u002For oxygenation at high field, without injection of gadolinium-based agent, for the detection of PAA in women with ongoing pregnancy between 30 and 38 weeks of gestation with risk factors for PPA.",[293],"Placenta; Implantation","2026-06-15",{"date":254,"type":29},{"date":297,"type":29},"2020-10-21",{"date":299,"type":20},"2026-10-21",{"name":35,"class":36},{"id":302,"slug":303,"hasResults":12,"nctId":304,"briefTitle":305,"officialTitle":305,"acronym":306,"eligibilityCriteria":307,"healthyVolunteers":201,"sex":17,"minAge":308,"maxAge":4,"enrollmentInfo":309,"targetDuration":4,"studyType":49,"phases":311,"briefSummary":312,"conditions":313,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":154},"100624909","imaging-of-electrical-properties-by-mri-investigation-of-age-related-changes-100624909","NCT07415759","Imaging of Electrical Properties by MRI: Investigation of Age-Related Changes","ELECTRA","Inclusion Criteria:\n\n* Person aged between 6 and 12, 20 and 40 years or aged 70 years and above\n* Person affiliated with a social security scheme or beneficiary of such a scheme\n* Person, or parent\u002Flegal guardian in the case of minors, who has received full information about the organization of the study and has signed the informed consent form\n\nExclusion Criteria:\n\n* Contraindication to undergoing an MRI examination or the presence of an MRI-incompatible medical device\n* Person presenting a pathology or tissue damage in the examined areas that may affect the measured MRI parameters\n* Pregnant woman, woman in labor, or breastfeeding mother\n* Person deprived of liberty by judicial or administrative decision, or persons undergoing psychiatric care","6 Years",{"count":310,"type":20},120,[51],"The goal of this study is to build a database of personalized EP (Electrical Properties) maps (accounting for age, anatomical location, and tissue complexity), obtained via MRI, to improve electromagnetic safety assessments, especially in the context of MRI. The EP values derived from this study are expected to be more accurate than current literature values, leading to more realistic specific absorption rate (SAR) modeling and improved patient safety. To investigate age-related differences, the study will include three distinct age groups.",[314],"Healthy Subjects","2026-06-11",{"date":317,"type":29},"2026-06-12",{"date":319,"type":29},"2026-04-04",{"date":321,"type":20},"2029-02-02",{"name":35,"class":36},{"id":324,"slug":325,"hasResults":12,"nctId":326,"briefTitle":327,"officialTitle":328,"acronym":329,"eligibilityCriteria":330,"healthyVolunteers":12,"sex":17,"minAge":46,"maxAge":4,"enrollmentInfo":331,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":333,"conditions":334,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":338,"completionDateStruct":339,"leadSponsor":341,"locationsCount":4},"100642679","prognostic-value-of-177lutetium-psma-single-photon-emission-tomography-and-timing-of-response-100642679","NCT07643935","Prognostic Value of 177Lutetium-PSMA Single Photon Emission Tomography and Timing of Response","Prognostic Value of [¹⁷⁷Lu]Lu-PSMA SPECT and Timing of RECIP Assessment in mCRPC","RECIP","Inclusion Criteria:\n\n* Patients with metastatic castration-resistant cancer who received at least two cycles of 177Lu-PSMA\n\nExclusion Criteria:\n\n* Patients who refused to have their data used for research purposes",{"count":332,"type":20},280,"177Lutetium-PSMA-617 is an established treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). Early response assessment is critical for optimizing patient management. Response Evaluation Criteria in Prostate Imaging (RECIP) 1.0, initially developed for Positon Emission Tomography (PET) with 68Ga-PSMA, have demonstrated prognostic value, particularly after two treatment cycles. Recent studies suggest that SPECT at cycle 2 provides prognostic information, although it reflects only the first treatment cycle, whereas PET-based RECIP, assessed after cycle 2, captures the effect of two cycles. This study aims to evaluate the prognostic value of quantitative 177Lu-PSMA-SPECT biomarkers and determine the optimal timing for RECIP-based assessment.",[335],"Therapy-Associated Cancer","2026-06-10",{"date":317,"type":29},{"date":63,"type":20},{"date":340,"type":20},"2026-12-01",{"name":35,"class":36},{"id":343,"slug":344,"hasResults":12,"nctId":345,"briefTitle":346,"officialTitle":347,"acronym":348,"eligibilityCriteria":349,"healthyVolunteers":12,"sex":17,"minAge":46,"maxAge":4,"enrollmentInfo":350,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":352,"conditions":353,"keywords":358,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":369,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":37},"100575902","msept9-biomarker-for-predicting-hepatocellular-carcinoma-occurrence-in-patients-with-cirrhosis-100575902","NCT06778317","mSEPT9 Biomarker for Predicting Hepatocellular Carcinoma Occurrence in Patients With Cirrhosis","Evaluation of the Circulating Epigenetic Biomarker mSEPT9 for Predicting the Occurrence of Hepatocellular Carcinoma in Patients With Cirrhosis: A Prospective Multicenter Trial (SEPT9_SuRV)","SEPT9_SuRV","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Patients diagnosed with cirrhosis confirmed by clinical, biochemical, radiological, or histological criteria.\n* Cirrhosis attributable to one or more of the following etiologies: alcohol, hepatitis C (HCV), hepatitis B (HBV), nonalcoholic steatohepatitis (NASH), hemochromatosis, autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, or cryptogenic causes.\n* Patients actively followed in one of the participating study centers.\n* Patients affiliated with a social security program or equivalent.\n* Patients with a body weight greater than 45 kg.\n* Patients who have been fully informed about the study procedures and have provided oral informed consent.\n\nExclusion Criteria:\n\n* History of hepatocellular carcinoma (HCC).\n* History of any other primary or secondary malignant liver tumor.\n* Diagnosis of malignancy or hematologic disorders within the past 5 years (without time limitation for hematologic malignancies).\n* Patients currently undergoing hemodialysis.\n* Pregnant or breastfeeding women.\n* Individuals under legal protection (e.g., guardianship, curatorship) or unable to provide consent.\n* Minors or individuals younger than 18 years.\n* Individuals deprived of liberty by judicial or administrative order.\n* Patients with psychiatric conditions receiving care under legal constraints (e.g., articles L.3212-1 and L.3213-1).\n* Patients unable to comply with the study protocol requirements.",{"count":351,"type":20},400,"This study aims to evaluate the role of the circulating epigenetic biomarker mSEPT9 in predicting the risk of hepatocellular carcinoma (HCC) in patients with cirrhosis. HCC is a primary liver cancer that frequently develops in individuals with cirrhosis, and early detection is critical for improving outcomes. This research involves 400 patients with cirrhosis who will be followed every six months for up to 60 months. During these visits, blood samples will be collected to analyze mSEPT9 levels. By identifying changes in this biomarker, the study seeks to improve early diagnosis and personalize surveillance strategies, potentially enhancing patient survival and quality of life.",[354,355,356,357],"Hepatocellular Carcinoma (HCC)","Cirrhosis","Risk Prediction for Liver Cancer","Epigenomics",[359,355,360,361,362,363,364,365,366,357,367],"Hepatocellular Carcinoma","mSEPT9 Biomarker","Epigenetics","Risk Prediction","Liver Cancer Surveillance","Prospective Cohort Study","Non-Invasive Biomarkers","Personalized Medicine","Risk Stratification","2026-06-08",{"date":336,"type":29},{"date":371,"type":29},"2025-06-03",{"date":373,"type":20},"2033-06-03",{"name":35,"class":36},{"id":376,"slug":377,"hasResults":12,"nctId":378,"briefTitle":379,"officialTitle":380,"acronym":381,"eligibilityCriteria":382,"healthyVolunteers":12,"sex":17,"minAge":46,"maxAge":98,"enrollmentInfo":383,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":385,"conditions":386,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":388,"lastUpdatePostDateStruct":389,"startDateStruct":391,"completionDateStruct":393,"leadSponsor":395,"locationsCount":37},"100596608","ex-vivo-evaluation-on-human-tissue-of-the-binding-of-experimental-radiolabeled-ligands-100596608","NCT07047677","Ex Vivo Evaluation on Human Tissue of the Binding of Experimental Radiolabeled Ligands","Ex Vivo Evaluation of Experimental Radiolabeled Ligand Binding in Human Tissue Using Autohistoradiography HERO (Human Ex-vivo RadiOligand) Platform","HERO","Inclusion Criteria:\n\n* Patients who underwent surgical resection at the Nancy University Hospital after 2019 (Information provided in the welcome booklet or on posters displayed in waiting rooms, mentioning the possible use of data or resection specimens, unless otherwise stated).\n* No documented objection, in accordance with the MR004 methodology.\n* Frozen human tissues (slides, blocks, or sections) from surgical resection or biopsy, transmitted by the CRB or the biopathology department.\n* Samples are fully anonymized before being made available for analysis.\n\nExclusion Criteria:\n\n* • Unusable tissue (degraded, insufficient, contaminated, poorly preserved).\n\n  * Lack of traceability of the material.\n  * Explicit opposition from the patient to the use of their tissue for research.",{"count":384,"type":20},300,"The HERO project aims to structure an ex vivo screening platform, based on anonymized human tissues, to early assess the tissue fixation of experimental ligands in an ethical, translational approach that complies with the principles of the 3Rs (Replacement, Reduction, Refinement).",[387],"Tissue Model","2026-06-03",{"date":390,"type":29},"2026-06-04",{"date":392,"type":29},"2025-11-01",{"date":394,"type":20},"2030-09-01",{"name":35,"class":36},{"id":397,"slug":398,"hasResults":12,"nctId":399,"briefTitle":400,"officialTitle":401,"acronym":402,"eligibilityCriteria":403,"healthyVolunteers":201,"sex":17,"minAge":46,"maxAge":404,"enrollmentInfo":405,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":407,"conditions":408,"keywords":411,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":413,"lastUpdatePostDateStruct":414,"startDateStruct":416,"completionDateStruct":418,"leadSponsor":420,"locationsCount":37},"100639539","subjective-assessment-of-spatial-orientation-abilities-in-alzheimers-disease-100639539","NCT07616063","Subjective Assessment of Spatial Orientation Abilities in Alzheimer's Disease","Evaluation Subjective Des CApacités d'Orientation sPatialE Dans la mAladie D'Alzheimer","ESCAPE-AD","Inclusion Criteria:\n\nFor all subjects :\n\n* Native French speakers\n* Independent mobility: (minimum mobility range of 3 (i.e., neighborhood) on the LSA-F assessment of the mobility zone scale)\n* Person affiliated with a social security system or beneficiary of such a system\n\nPatients (Subgroup A1) and healthy control subjects (Group C):\n\n* Individuals who have received complete information about the clinical research organization and have signed their written informed consent\n* Patients (Subgroups A2 and A3) and Companions (Group B) Individuals who have received complete information about the clinical research and have agreed to participate\n\nPatients (group A):\n\n* Aged 55 to 85\n* Diagnosis of probable Alzheimer's disease (NINCDR-ADRDA diagnostic criteria)\n* Score of 4 or less on the Hachinski Ischemic Scale\n* Score of 20 or higher on the Folstein MMSE (Mini Mental State Examination)\n* In the case of specific treatment for Alzheimer's disease (anticholinesterase and memantine treatments), treatment stability for \\> 15 days\n* Able to walk independently, i.e., without assistance, whether human or technical, except for a simple cane\n\nCaregivers (group B):\n\n* Caregivers of a person with dementia included in group A, with regular contact (at least 10 hours per week, spread over a minimum of 3 times per week)\n* Healthy control subjects (group C):\n* Aged 55 to 85\n* Able to walk independently, i.e., without assistance, whether human or technical, except for a single cane\n* Normal performance on the Folstein Mini-Mental State Examination (MMSE), according to GRECO (Cognitive Assessment Task Force) standards\n\nExclusion Criteria:\n\nFor all subjects:\n\n* Adults subject to legal protection measures (guardianship, curatorship, judicial protection)\n* Adults unable to give their consent\n* Persons deprived of their liberty by judicial or administrative decision, persons receiving psychiatric care pursuant to Articles L. 3212-1 and L. 3213-1.\n* Persons capable of giving consent but unable to read French\n* Persons capable of giving consent but unable to write\n* One of the members of the patient\u002Fcaregiver dyad refusing to participate in the study.\n\nPatients (subgroup A1) and healthy control subjects (group C):\n\n* Sensory or phasic deficit interfering with the task.\n* History of moderate or severe head trauma (with loss of consciousness).\n* Change in psychotropic treatment less than 48 hours before the tests\n* Chronic alcoholism\n* Severe depression (score greater than or equal to 10 on the GDS-15 Geriatric Depression Scale)\n* Presence of other clinically significant psychiatric or neurological conditions (except Alzheimer disease for case subjects)","85 Years",{"count":406,"type":20},330,"Difficulty orienting oneself and finding one's way around the environment, also known as \"topographical disorientation\" (TD) or \"spatial disorientation\" (SD), is a common and often early symptom of Alzheimer's disease (AD) that affects people's independence and well-being. Being able to identify it is therefore crucial in order to provide appropriate support.\n\nIt cannot be assessed using conventional psychometric tests due to its low ecological validity. Several subjective assessment scales have been created to screen for SD \"spatial disorientation\" and assess its functional and psychological impact. However, none of these scales have been translated and validated in French. As a result, DS is not assessed in routine clinical practice.\n\nAmong these scales, the Wayfinding Questionnaire (WQ) explores three dimensions: spatial orientation, distance estimation, and spatial anxiety. This questionnaire has undergone psychometric validation studies in its original Dutch version for a population with mild post-stroke , and norms for the general population have been published.\n\nOur team translated this questionnaire into French (i.e., \"Questionnaire d'Orientation Spatiale\" (QOS)) and adapted it cross-culturally to preserve the qualities of the measurement. A \"Caregiver\" version was also created, taking into account the anosognosia known to occur in AD. Primary Objective : Evaluate the psychometric properties of the Spatial Orientation Questionnaire (SOSQ) (i.e., the French translation and adaptation of the Wayfinding Questionnaire) in assessing spatial orientation disorders in patients with Alzheimer's disease, in both its \"patient\" and \"caregiver\" versions. Secondary objective : Evaluate the acceptability of the Spatial Orientation Questionnaire (SOC) in its \"patient\" and \"caregiver\" versions.",[409,410],"Alzheimer s Disease","Spatial Orientation",[412],"Alzheimer s disease","2026-05-26",{"date":415,"type":29},"2026-05-29",{"date":417,"type":20},"2026-05",{"date":419,"type":20},"2026-11",{"name":35,"class":36},{"id":422,"slug":423,"hasResults":12,"nctId":424,"briefTitle":425,"officialTitle":426,"acronym":427,"eligibilityCriteria":428,"healthyVolunteers":12,"sex":17,"minAge":46,"maxAge":429,"enrollmentInfo":430,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":432,"conditions":433,"keywords":435,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":438,"startDateStruct":439,"completionDateStruct":441,"leadSponsor":443,"locationsCount":4},"100638746","fast-cardiac-bone-spect-czt-in-transthyretin-cardiac-amyloidosis-100638746","NCT07605741","Fast Cardiac Bone SPECT-CZT in Transthyretin Cardiac Amyloidosis","Fast Cardiac Bone 360° SPECT-CZT Accurately Reproduces Planar Perugini ≥ 2 Classification With High Reproducibility in Transthyretin Cardiac Amyloidosis","PeakAmyL","Inclusion Criteria:\n\n* Patients who were routinely referred for bone scintigraphy for suspected transthyretin cardiac amyloidosis (ATTR-CA) between April 2024 and April 2025.\n\nExclusion Criteria:\n\n* Patients who object to the use of their data","95 Years",{"count":431,"type":20},200,"Transthyretin cardiac amyloidosis (ATTR-CA) is traditionally diagnosed using planar bone scintigraphy with a Perugini visual score ≥ 2. Fast cardiac CZT-SPECT will be evaluated for its ability to reproduce this classification and provide reproducible quantitative myocardial uptake metrics.",[434],"Cardiac Amyloidosis",[436],"Cardiac amyloidosis, Bone scans, CZT, SPECT-CT, Perugini","2026-05-18",{"date":413,"type":29},{"date":440,"type":20},"2026-05-30",{"date":442,"type":20},"2026-07-30",{"name":35,"class":36},{"id":445,"slug":446,"hasResults":12,"nctId":447,"briefTitle":448,"officialTitle":449,"acronym":450,"eligibilityCriteria":451,"healthyVolunteers":12,"sex":17,"minAge":46,"maxAge":4,"enrollmentInfo":452,"targetDuration":4,"studyType":49,"phases":454,"briefSummary":455,"conditions":456,"keywords":459,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":463,"lastUpdatePostDateStruct":464,"startDateStruct":466,"completionDateStruct":467,"leadSponsor":469,"locationsCount":4},"100629181","prospective-study-of-postictal-psychotic-symptoms-occuring-after-video-eeg-monitoring-in-focal-epilepsies-100629181","NCT07471334","Prospective Study of Postictal Psychotic Symptoms Occuring After Video-EEG Monitoring in Focal Epilepsies","Incidence of Postictal Psychotic Symptoms After a Video-EEG Monitoring : Impact of Focal Epileptic Seizures","INSPEV","Inclusion Criteria:\n\n* confirmed diagnosis of drug-resistant focal epilepsy\n* hospitalization for at least 5 days video-EEG (or SEEG) monitoring\n* capable of providing informed consent, able to communicate in French, and covered by a national health insurance plan\n\nExclusion Criteria:\n\n* Patients presenting with psychotic symptoms at baseline (V1), or who have had recent modifications (less than 15 days before admission) to their antiepileptic or psychotropic medications, will be excluded to reduce confounding factors in the assessment of postictal psychotic symptoms.",{"count":453,"type":20},110,[51],"Psychotic disorders are up to eight times more prevalent in patients with epilepsy compared to the general population. Among them, postictal psychosis (PIP) is a severe complication of focal epilepsy, characterized by a brief psychotic episode emerging days after a seizure. This project investigates a potentially attenuated and under-recognized manifestation-postictal psychotic symptoms (PPs)-that may arise following hospitalization in a video-EEG monitoring unit and might serve as an early indicator for future PIP.\n\nThe investigators hypothesize that the incidence of PPs is substantially higher than the 3% PIP prevalence reported in the literature and that their occurrence correlates with the intensity of epileptic activity triggered during video-EEG monitoring. The study has three main objectives: (1) to determine the incidence of PPs in patients with drug-resistant focal epilepsy, (2) to identify predictive factors associated with PPs, and (3) to assess the validity of the PQ-16 screening tool in this clinical context.\n\nA prospective monocentric study will be conducted in the video-EEG unit of Nancy University Hospital. One hundred and ten patients hospitalized for at least five days will be included. Psychiatric assessments will include standardized clinical interviews, Brief Psychiatric Rating Scale (BPRS) scoring, and self-report questionnaires. These evaluations will take place at three timepoints: baseline (V1), 3-5 days post-discharge (V2), and two months post-discharge (V3).\n\nThis study aims to facilitate the early identification of PPs and support the development of preventive strategies, ultimately improving psychiatric care and overall management in patients with epilepsy.",[457,458],"Focal Epilepsy With and Without Secondary Generalization","Psychotic Symptoms",[460,461,462],"postictal psychosis","epileptic psychoses","psychoses of epilepsy","2026-05-13",{"date":465,"type":29},"2026-05-15",{"date":63,"type":20},{"date":468,"type":20},"2028-09-01",{"name":35,"class":36},{"id":471,"slug":472,"hasResults":12,"nctId":473,"briefTitle":474,"officialTitle":474,"acronym":475,"eligibilityCriteria":476,"healthyVolunteers":12,"sex":17,"minAge":46,"maxAge":4,"enrollmentInfo":477,"targetDuration":4,"studyType":49,"phases":479,"briefSummary":480,"conditions":481,"keywords":483,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":486,"startDateStruct":488,"completionDateStruct":490,"leadSponsor":492,"locationsCount":4},"100636948","pilot-study-on-the-feasibility-of-high-energy-collimation-with-optimized-geometry-on-a-veriton-czt-camera-100636948","NCT07572318","Pilot Study on the Feasibility of High-energy Collimation With Optimized Geometry on a VERITON™ CZT Camera","HELIOS","Inclusion Criteria:\n\n* patients with multiple known lesions (≥ 2 metastases or lesions of other types) who, as part of their clinical management, require either (i) a 99mTc-HDP bone scan, or (ii) a post-therapeutic 177Lu-PSMA scan, or (iii) a post-therapeutic 131I scintigraphy.\n* Person who has undergone a preliminary clinical examination appropriate for clinical research.\n* Adult subject who has received complete information about the research and has signed the informed consent form.\n* General condition, WHO ≤ 2, and ability to remain lying down without moving for nearly an hour.\n\nExclusion Criteria:\n\n* Subjects with a contraindication, according to the target examination group, to injection of 99mTc-HDP (Technescan HDP, Curium Pharma), 177Lu-PSMA (Pluvicto®, Novartis), or 131I (131I sodium iodide for therapy, Curium Pharma) .\n* Subjects covered by Articles L. 1121-5, L. 1121-7, and L1121-8 of the Public Health Code.\n* Pregnant women, women in labor, or breastfeeding mothers.\n* Subjects subject to legal protection measures (guardianship, curatorship, judicial protection).\n* Subjects unable to give their consent.\n* Subjects deprived of their liberty by a judicial or administrative decision, persons receiving psychiatric care pursuant to Articles L. 3212-1 and L.3213-1.",{"count":478,"type":20},18,[51],"Functional imaging using scintigraphy plays a major role in the diagnosis and monitoring of many diseases, particularly thanks to its ability to perform whole-body examinations with high contrast. The indications and use of scintigraphy have increased in recent years, particularly in connection with the development of internal vectorized radiotherapy. This therapeutic approach is based on the administration of radiotracers that enable targeted irradiation of tumor cells, whose biodistribution throughout the body can be analyzed and quantified using scintigraphy, particularly with iodine-131 and lutetium-177.\n\nThe recent boom in scintigraphy is also linked to the development of new 360° geometry CZT-SPECT cameras, which enable rapid tomographic acquisitions of the entire body with significantly improved image quality compared to conventional cameras. These systems use mobile CZT semiconductor detectors that dynamically scan the anatomical regions of interest.\n\nCZT detectors are combined with a collimation system consisting of tungsten septa, which are essential for the directional filtering of gamma photons. Unlike conventional scintigraphic cameras, where collimators can be changed or adjusted according to the energy of the detected photons, CZT-SPECT 360° cameras generally rely on fixed collimation, which cannot be changed.",[482],"Cancer",[484,485],"scintigraphy","scintigraphy post therapeutic",{"date":487,"type":29},"2026-05-07",{"date":489,"type":20},"2026-05-01",{"date":491,"type":20},"2027-05-01",{"name":35,"class":36},{"id":494,"slug":495,"hasResults":12,"nctId":496,"briefTitle":497,"officialTitle":498,"acronym":499,"eligibilityCriteria":500,"healthyVolunteers":12,"sex":17,"minAge":46,"maxAge":4,"enrollmentInfo":501,"targetDuration":4,"studyType":49,"phases":503,"briefSummary":504,"conditions":505,"keywords":508,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":512,"lastUpdatePostDateStruct":513,"startDateStruct":514,"completionDateStruct":516,"leadSponsor":518,"locationsCount":37},"100636809","point-of-care-testing-inr-in-antiphospholipid-syndrome-100636809","NCT07570511","Point of Care Testing INR in Antiphospholipid Syndrome","Explaining the Differences Between Capillary INR and Plasma INR in Patients With Antiphospholipid Syndrome","POCTAS","Inclusion Criteria:\n\n* Patients with APS treated with vitamin K antagonists (VKAs)\n\n  * Patients with an LA profile without aCL or anti-β2GPI (isolated LA)\n  * Patients with an LA and aCL + anti-β2GPI profile (triple positivity)\n  * Patients with another biological profile (other than isolated LA or triple positivity)\n* Control patients without aCL or anti-β2GPI treated with VKAs\n* Adult patients\n* Patients who have undergone a prior clinical examination appropriate for the research\n* Individuals who have received complete information on the organization of the research and have not objected to their participation and the use of their data\n* Patients covered by a social security scheme\n\nExclusion Criteria:\n\n* Patients with antiphospholipid syndrome (APS) not treated with vitamin K antagonists (VKAs)\n* Women of childbearing age without effective contraception\n* Persons covered by Articles L. 1121-5, L. 1121-7, and L. 1121-8 of the French Public Health Code:\n\n  * Pregnant, parturient, or breastfeeding women\n  * Unemancipated minors\n  * Adults under legal protection (guardianship, curatorship, or protective supervision)",{"count":502,"type":20},150,[51],"Antiphospholipid syndrome (APS) is an autoimmune and prothrombotic disorder that can affect up to 10% of young people experiencing a thrombotic event. Its treatment relies on long-term anticoagulation with vitamin K antagonists (VKAs). Direct oral anticoagulants, which are simpler to use because they do not require regular blood monitoring, are contraindicated because they are associated with an increased risk of thrombotic recurrence in some patients with APS.\n\nPatients with APS receive VKAs and must regularly have their Index Normalized Ratio (INR) measured via a cumbersome venous blood draw. Capillary INR measurement systems are already used in certain situations, such as in patients with mechanical heart valves. The use of these systems improves the quality of life of these patients and, above all, the stability of VKA therapy, thus preventing potentially serious hemorrhagic complications or thrombotic recurrences.\n\nIn antiphospholipid syndrome (APS), these systems are discouraged due to perceived differences between capillary and venous INR (the reference method). However, among the few studies on the subject, none demonstrated significant discrepancies between patients with APS and controls, and when such discrepancies were observed, the origin of this variability could not be determined. We hypothesize that the biological profile of antiphospholipid antibodies is responsible for the INR differences.",[506,507],"Antiphospholipid Syndrome","Vitamine K Antagonist (VKA) Treatment",[509,510,511],"INR","vitamin K","Antiphospholipid","2026-04-30",{"date":108,"type":29},{"date":515,"type":20},"2026-06-01",{"date":517,"type":20},"2028-12-01",{"name":35,"class":36},{"id":520,"slug":521,"hasResults":12,"nctId":522,"briefTitle":523,"officialTitle":524,"acronym":525,"eligibilityCriteria":526,"healthyVolunteers":12,"sex":17,"minAge":46,"maxAge":4,"enrollmentInfo":527,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":528,"conditions":529,"keywords":533,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":537,"lastUpdatePostDateStruct":538,"startDateStruct":539,"completionDateStruct":540,"leadSponsor":541,"locationsCount":37},"100635899","perioperative-pharmacokineticpharmacodynamic-target-attainment-of-piperacillin-during-major-hepatic-and-pancreatic-surgery-100635899","NCT07558681","Perioperative Pharmacokinetic\u002FPharmacodynamic Target Attainment of Piperacillin During Major Hepatic and Pancreatic Surgery","PROPHTAZ: Evaluation of Pharmacokinetic\u002FPharmacodynamic Target Attainment of Piperacillin During Major Hepatic and Pancreatic Surgery, a Prospective Observational Pharmacokinetic Study","PROPHTAZ","Inclusion Criteria:\n\n* Adults \\> or = to 18 years old\n* Scheduled for major hepatic or pancreatic surgery\n* Receiving piperacillin\u002Ftazobactam as perioperative antibiotic prophylaxis according to guidelines\n\nExclusion Criteria:\n\n* decline to participate\n* Known allergy of beta-lactam",{"count":203,"type":20},"Hepatic and pancreatic surgeries are associated with a high risk of surgical site infections, particularly in patients with preoperative biliary drainage, which is frequently associated with bacterial colonization of bile. In this context, perioperative antibiotic prophylaxis is essential, and recent guidelines recommend the use of piperacillin\u002Ftazobactam in selected high-risk patients.\n\nHowever, piperacillin, like other β-lactam antibiotics, exhibits pharmacokinetic variability that may be exacerbated during major surgery due to factors such as fluid shifts, hypoalbuminemia, and changes in volume of distribution. These alterations may result in suboptimal antibiotic exposure during the perioperative period, potentially compromising prophylactic efficacy.\n\nDespite these concerns, standard dosing regimens remain unchanged across different types of major abdominal surgery, including hepatic and pancreatic procedures, which differ significantly in terms of duration, physiological impact, and intraoperative management.\n\nThe PROPHTAZ study is a prospective, single-center observational pharmacokinetic study designed to evaluate whether standard perioperative administration of piperacillin\u002Ftazobactam achieves predefined pharmacokinetic\u002Fpharmacodynamic (PK\u002FPD) targets in patients undergoing hepatic or pancreatic surgery. The primary objective is to determine the proportion of patients achieving adequate PK\u002FPD exposure during surgery. Secondary objectives include describing perioperative plasma concentrations, assessing pharmacokinetic variability, identifying factors associated with target non-attainment, and comparing outcomes between surgical subgroups.\n\nThis study aims to provide clinically relevant data to assess the adequacy of current prophylactic dosing strategies and to support potential optimization of antibiotic administration in high-risk surgical patients.",[530,531,532],"Antibiotic Prophylaxis","Pancreatic Surgey","Hepatic Surgery",[534,535,536],"PK\u002FPD target atttainment","piperacillin","surgical site infection","2026-04-27",{"date":512,"type":29},{"date":489,"type":20},{"date":491,"type":20},{"name":35,"class":36},{"id":543,"slug":544,"hasResults":12,"nctId":545,"briefTitle":546,"officialTitle":547,"acronym":548,"eligibilityCriteria":549,"healthyVolunteers":201,"sex":17,"minAge":46,"maxAge":4,"enrollmentInfo":550,"targetDuration":4,"studyType":49,"phases":552,"briefSummary":553,"conditions":554,"keywords":556,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":562,"lastUpdatePostDateStruct":563,"startDateStruct":565,"completionDateStruct":567,"leadSponsor":569,"locationsCount":37},"100511114","development-and-evaluation-of-an-algorithm-for-vascular-access-management-100511114","NCT05935228","Development and Evaluation of an Algorithm for Vascular Access Management","Development and Evaluation of an Algorithm for Vascular Access Management - ALCOV Pilot Study","ALCOV","Inclusion Criteria:\n\n* Patient inclusion criteria: adult patients, initially requiring at least one peripheral venous catheter (PVC), having given their consent for the study.\n* Inclusion criteria for healthcare professionals: Nurses, specialized nurses (IADE) and physicians attached to the department.\n\nExclusion Criteria:\n\nPatient exclusion criteria :\n\n* Minor patients\n* Patients under curators or guardianship\n* Patients who are non-communicative or unable to give consent\n* Patients not requiring a peripheral venous catheter, polytrauma patients and patients in shock (septic, hemorrhagic, cardiogenic, spinal, specific to certain centers and equipped upstream)\n* Patients who already have catheters on arrival.\n\nExclusion criteria for healthcare professionals: any professional not attached to the department and other professional categories.",{"count":551,"type":20},794,[51],"Two billion catheters are placed annually worldwide. Of all the people requiring vascular access, nearly a quarter have Difficult Intravenous access (DIVA), a source of multiple punctures. The increased risk of haematomas, haemorrhages, infection, pain and associated trauma is responsible for increased human costs and economic impact.\n\nTo limit the risks posed by the DIVA, practitioners have solutions such as the per-bone line, other types of lines, and placement of peripheral venous catheter with ultrasound or transluminescence. However, these solutions are not always applicable, depending on the care situation (non-substitutable venous access, fragile patient, etc.) or on the technical platform (available personnel and training, configuration of the premises, available equipment). Moreover, these actions are often taken after failures, in a non-anticipated and non-consensual manner.\n\nIn order to assess the risk of DIVA, F.Van Loon et al developed in 2016, and then modified in 2018, a DIVA Scale (the A-DIVA Scale) which allows a rapid scoring upstream of peripheral venous catheter placement to classify patients according to the risk of DIVA.\n\nComposed of five items (non-palpable and non-visible vein, diameter \\\u003C 3mm, history of DIVA, operator experience) worth one point each, the score allows three categories to be established: \"low risk\", \"moderate risk\", \"high risk\". The study showed that the proportion of first puncture failures increased with the risk of the patients (defined according to the categorized score).\n\nThe use of a tool such as the A-DIVA Scale is of interest if it allows the definition of actions to be taken in relation to the risk it identifies. In view of this, it appears essential to optimize the management of peripheral venous catheters, particularly for patients with DIVAs. The aim of this study is to develop a graduate and specific response to the issue of multiple punctures. Our project is to create and evaluate a specific algorithm, consisting of a risk assessment (the A-DIVA Scale) and a co-construct decision-making tree (the A-DIVA Tool). Built on the basis of objective clinical data collection and adapted to the possibilities and competencies, this new tool would bring real benefits to the patient in terms of safety (reduction of risks) and comfort (reduction of pain and duration of management), as well as a medico-economic benefit for the institutions. To date, such an algorithm does not exist and its beneficial effects have not been evaluated.",[555],"Peripheral Venous Access",[557,558,559,560,561],"Difficult Intravenous Access (DIVA)","Difficult Intravenous Access Scale (A-DIVA Scale)","Algorithm","Peripheral venous catheter","Decision-making tree","2026-04-24",{"date":564,"type":29},"2026-04-29",{"date":566,"type":29},"2023-12-05",{"date":568,"type":20},"2027-06-09",{"name":35,"class":36},{"id":571,"slug":572,"hasResults":12,"nctId":573,"briefTitle":574,"officialTitle":575,"acronym":576,"eligibilityCriteria":577,"healthyVolunteers":12,"sex":17,"minAge":46,"maxAge":4,"enrollmentInfo":578,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":579,"conditions":580,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":582,"lastUpdatePostDateStruct":583,"startDateStruct":585,"completionDateStruct":587,"leadSponsor":588,"locationsCount":37},"100634381","real-time-imaging-to-improve-lung-cancer-diagnosis--comparing-confocal-laser-endomicroscopy-cle-with-standard-biopsy-for-quicker-and-safer-detection-of-non-small-cell-lung-cancer-100634381","NCT07538947","Real-Time Imaging to Improve Lung Cancer Diagnosis : Comparing Confocal Laser Endomicroscopy (CLE) With Standard Biopsy for Quicker and Safer Detection of Non-Small Cell Lung Cancer","Confocal Laser Endomicroscopy (CLE) Score for the Detection of Non-Small Cell Lung Cancer (NSCLC) and Rapid Surgical Decision-Making","SCORACLE","Inclusion Criteria:\n\n* Patient for whom endobronchial navigation-guided biopsy is indicated\n* Complete medical data (CLE images and histopathological results)\n\nExclusion Criteria:\n\n* Persons referred to in Articles L. 1121-5, L. 1121-7, and L. 1121-8 of the French Public Health Code:\n* Individuals under 18 years of age\n* Adult persons subject to legal protection measures (guardianship, curatorship, or judicial protection)\n* Adult persons unable to express their consent\n* Persons deprived of liberty by judicial or administrative decision, and persons receiving psychiatric care under Articles L. 3212-1 and L. 3213-1",{"count":19,"type":20},"The goal of this observational study is to evaluate whether confocal laser endomicroscopy (CLE) can improve the real-time diagnosis of non-small cell lung cancer (NSCLC) in patients undergoing bronchoscopic biopsy for suspected lung tumors. The main questions it aims to answer are:\n\n* Can a high-specificity CLE-based score accurately identify NSCLC during endoscopic procedures?\n* Can CLE imaging criteria improve biopsy yield and help differentiate histological subtypes (e.g., squamous cell carcinoma, adenocarcinoma, carcinoid tumors)?\n\nParticipants will:\n\n* Undergo standard bronchoscopic navigation procedures with additional real-time imaging using CLE and biopsy\n* Have CLE findings compared with standard histopathological analysis of biopsy samples",[581],"Non Small Cell Lung Cancer","2026-04-13",{"date":584,"type":29},"2026-04-20",{"date":586,"type":29},"2026-04-03",{"date":294,"type":20},{"name":35,"class":36},""]